Intelligence · Drug directory
Pipeline & Investigational Drugs
Investigational and clinical-stage compounds without US or EU marketing approval — linked to ClinicalTrials.gov programs and congress coverage.
Quick answer
Pipeline & investigational drugs: NovaPharmaNews tracks 1,610 pharmaceutical drugs in this segment. Investigational and clinical-stage compounds without US or EU marketing approval — linked to ClinicalTrials.gov programs and congress coverage.
-
coal tar solution
NULL
-
coconut oil
NULL
-
codeine linctus
NULL
-
codeine phosphate (may only be prescribed in linctuses, mixtures or mixtures for children)
NULL
-
collagenase (clostridium histolyticum)
XIAFLEX
-
collodion flexible
NULL
-
coronavirus (sars-cov-2) rna vaccine
DAICHIRONA PARTIAL CHANGE APPROVAL
-
coronavirus (sars-cov-2) rna vaccine (active ingredient: mafb-7256a)
DAICHIRONA (MONOVALENT, OMICRON XBB.1.5) PARTIAL CHANGE APPROVAL
-
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)
DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL
-
coronavirus (sars-cov-2) rna vaccine (active ingredients of bivalent original/omicron ba.1 vaccine: elasomeran and imelasomeran) (active ingredients of bivalent original/omicron ba.4-5 vaccine: elasomeran and davesomeran) (active ingredient of monovalent
SPIKEVAX (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.1) (BIVALENT, ORIGINAL/OMICRON BA.4-5) (MONOVALENT, OMICRON XBB.1.5) PARTIAL CHANGE APPROVAL
-
coronavirus (sars-cov-2) rna vaccine (active ingredients: elasomeran and davesomeran)
SPIKEVAX (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.4-5) PARTIAL CHANGE APPROVAL
-
coronavirus (sars-cov-2) rna vaccine (active ingredients: tozinameran and famtozinameran)
COMIRNATY RTU (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.4-5) PARTIAL CHANGE APPROVAL
-
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: elasomeran)
SPIKEVAX (PREVIOUSLY COVID-19 VACCINE MODERNA) (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL
-
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)
COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL
-
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: elasomeran and imelasomeran)
SPIKEVAX (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.1) PARTIAL CHANGE APPROVAL
-
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and famtozinameran)
COMIRNATY FOR 5 TO 11 YEARS OLD (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.4-5) PARTIAL CHANGE APPROVAL
-
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and riltozinameran)
COMIRNATY RTU (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.1) PARTIAL CHANGE APPROVAL
-
covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector)
JCOVDEN
-
covid-19 (sars-cov-2) vaccine (recombinant chimpanzee adenovirus vector)
VAXZEVRIA (NOTE 2)
-
creams
NULL
-
dabigatran etexilate methanesulfonate
PRADAXA
-
dabrafenib mesilate
TAFINLAR INITIAL APPROVAL
-
daclatasvir hydrochloride
DAKLINZA
-
daclatasvir hydrochloride/ asunaprevir/beclabuvir hydrochloride
XIMENCY
Frequently asked questions
How many pipeline drugs are listed?
1,610 drug profiles match this regulatory segment in our published index.
Where does approval data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.